Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Merck
Express Scripts
Moodys
Dow

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Patent: 9,605,064

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,605,064
Title:Methods and compositions for treatment of skin disorders
Abstract: The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNF.alpha. activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNF.alpha. activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNF.alpha. activity, such as psoriasis.
Inventor(s): Okun; Martin M. (Libertyville, IL), Hoffman; Rebecca S. (Wilmette, IL), Barker; Jonathan (London, GB)
Assignee: AbbVie Biotechnology Ltd (Hamilton, BM)
Application Number:12/859,181
Patent Claims:see list of patent claims

Details for Patent 9,605,064

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial AbbVie Biotechnology Ltd (Hamilton, BM) 2026-04-10 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial AbbVie Biotechnology Ltd (Hamilton, BM) 2026-04-10 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial AbbVie Biotechnology Ltd (Hamilton, BM) 2026-04-10 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial AbbVie Biotechnology Ltd (Hamilton, BM) 2026-04-10 RX Orphan search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial AbbVie Biotechnology Ltd (Hamilton, BM) 2026-04-10 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Moodys
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.